Purpose: To report the association of X-linked ichthyosis and pre-Descemet corneal dystrophy with a deletion of the steroid sulfatase gene (STS) detected with microarray-based comparative genomic hybridization (aCGH).
T he term ichthyosis refers to a "fish scale" appearance of the skin in patients afflicted with this condition. 1 Although ichthyosis may have a variety of etiologies, the term is most commonly used to describe the hereditary disorders of skin keratinization. The ichthyotic dermatoses are classified into 4 categories based on the mode of inheritance and the characteristic clinical manifestations: ichthyosis vulgaris (the most common), X-linked ichthyosis (XLI), lamellar ichthyosis, and bullous ichthyosiform erythroderma. 1,2 XLI, the second most common form of ichthyosis with a reported incidence of 1 in 1500 to 6000 males, usually presents within the first year of life with the appearance of large hyperpigmented scales primarily on the extensor surfaces of the limbs and on the side of the torso. 3, 4 While other areas of the body may be affected, the lower extremities usually demonstrate the most significant cutaneous changes after early childhood. 5 XLI is caused by a deficiency of the enzyme steroid sulfatase (STS; MIM 300747), which has been mapped to the Xp22.3 locus on the distal short arm of the X chromosome, a region associated with a high frequency of deletions. 6 Although 80% to 90% of XLI cases result from complete deletions of STS, a few case reports have described point mutations in the gene, and a small number of cases may be because of genetic alterations of the X chromosome that do not affect STS. 5, 7 XLI may occur solely as a skin disorder or be associated with other findings, such as ocular changes (up to 50%), cryptorchidism (20%), chondrodysplasia punctata, mental retardation, and epilepsy. 5 Several syndromes have been described that involve the deletion of STS and adjacent genes, such as Rud, Conradi, and Kallmann syndromes. 5 Ocular findings in ichthyoses are varied and include changes in the lids, conjunctiva, cornea, lens, and peripheral retina. 8, 9 In particular, the myriad corneal changes associated with XLI may involve all layers of the cornea and include epithelial irregularity, subepithelial and anterior stromal opacities, and punctate posterior stromal opacities located immediately anterior to the Descemet membrane. [10] [11] [12] [13] Pre-Descemet corneal dystrophy is characterized by the presence of such posterior stromal opacities thought to represent the accumulations of cholesterol sulfate. 9, 12 Given the infrequency with which ophthalmologists encounter and diagnose this and other disorders associated with dystrophic corneal opacities, we are interested in the utility of molecular genetic analysis to aid the ophthalmologist in the differentiation between dystrophic and nondystrophic corneal disorders. Therefore, we present a case of an individual with clinical features consistent with pre-Descemet corneal dystrophy and ichthyosis in whom copy number variation (CNV) analysis confirmed the diagnosis of XLI by identifying an Xp22.3 microdeletion containing STS.
MATERIALS AND METHODS
The authors followed the tenets of the Declaration of Helsinki in the treatment of the subject reported. Study approval was obtained from the Institutional Review Board at the University of California, Los Angeles (UCLA IRB #11-000020).
After informed consent was obtained, a saliva sample (Oragene saliva collection kits; DNA Genotek, Inc, Ontario, Canada) was collected from the patient and genomic DNA extraction was subsequently performed. The 10 exons of STS were amplified by polymerase chain reaction (PCR) using the 9 primer pairs previously described by Liao et al. 14 MO), 4.0 mL of 1.25 mM dNTPs, 2.0 mL of 25 mM magnesium chloride, 0.2 mL of each primer (10 mM), 0.5 mL of RedTaq genomic DNA polymerase (Sigma-Aldrich), and approximately 30 ng of genomic DNA. The reaction was run in an iCycler Thermal Cycler (Bio-Rad, Hercules, CA) at 95°C for 3 minutes followed by 25 cycles at 95°C for 3 minutes, 50°C to 68°C gradient for 20 seconds, 72°C for 45 seconds, and 72°C for 10 seconds.
A sample of the patient's genomic DNA was submitted to the UCLA Clinical Microarray Core for CNV analysis using microarray-based comparative genomic hybridization (CytoScan HD array; Affymetrix, Santa Clara, CA). Results were analyzed using the CNV analysis tools within the Partek Genomic Suite Software (Partek Inc, St Louis, MO).
RESULTS

Case Report
A 49-year-old man was referred to one of the authors (A. J.A.) for evaluation of bilateral corneal opacities, first diagnosed approximately 6 years before. The patient's medical history was significant for a chronic dermatologic disorder characterized by excessive flaking and scaling, which the patient's 3 brothers and maternal grandfather had as well ( Fig. 1) . External examination revealed thickening and scaling of the skin over the arms and extensor surfaces of the legs consistent with ichthyotic changes (Fig. 2) . The corrected visual acuities measured 20/15 in the right eye and 20/30 in the left eye, improving with pinhole to 20/25. The slit-lamp biomicroscopic examination of each cornea demonstrated granular gray-white opacities in the posterior corneal stroma that did not involve the peripheral 2 to 3 mm of each cornea (Fig. 3) . No corneal endothelial abnormalities were observed, and the remainder of the ocular examination in each eye was unremarkable. Specular microscopic imaging of the central corneal endothelium in each eye demonstrated a regular endothelial cell mosaic, with an estimated cell density of 2817 and 2849 cells per square millimeter in the right and left eyes, respectively.
The PCR amplification of each of the 10 exons of STS using the patient's genomic DNA failed to generate any amplicons. However, each exon was successfully amplified using genomic DNA from control samples. Additionally, a region of the ZEB1 gene was successfully amplified using patient and control genomic DNA. As these results were consistent with a deletion of STS, CNV analysis was performed, which confirmed an approximately 1.7 megabase deletion in the Xp22.31 region, containing STS (Fig. 4) . In addition, a number of other genes were deleted, including VCX3A (variable charge, X-linked 3A), RPS27AP17 (ribosomal protein S27a pseudogene 17), HDHD1 (haloacid dehalogenase-like hydrolase domain containing 1), MIR4767 (microRNA 4767), VCX (variable charge, X-linked), PNPLA4 (patatin-like phospholipidase domain containing 4), LOC100506502 (uncharacterized miscellaneous RNA), MIR651 (microRNA 651), and VCX2 (variable charge, X-linked 2).
DISCUSSION
Punctate corneal stromal opacities located anterior to the Descemet membrane, the most common ocular manifestation associated with XLI, usually appear during early adulthood and are seen in up to 50% of affected male patients and 25% of female carriers. 6, 9, 15, 16 These opacities were once thought to be invariably present in later life, but subsequent studies have failed to demonstrate an association between age and prevalence of corneal opacities. 17 The stromal opacities typically do not affect vision, although a few cases of affected individuals symptomatic from associated epithelial irregularities, subepithelial stromal opacities, and recurrent corneal erosions have been reported. [11] [12] [13] [18] [19] [20] Although skin changes in XLI are attributed to a deficiency of the enzyme steroid sulfatase encoded by STS, the etiology of the associated corneal changes is still debated. Steroid sulfatase is found throughout the body, including the epidermis, where it is thought to play a role in the steroid production and lipid regulation of the stratum corneum. 7 As steroid sulfatase deficiency leads to elevated plasma levels of cholesterol sulfate, the corneal opacities have been postulated to represent focal accumulations of cholesterol sulfate. 12 Electron microscopic examination of a corneal button from an individual with XLI and pre-Descemet corneal dystrophy has revealed electron-dense polymorphic and lamellated material in the posterior corneal stroma anterior to the Descemet membrane, suggestive of cholesterol sulfate aggregates. 12 Another hypothesis is that the opacities identified clinically are caused by structural and physiological changes in stromal tissue indirectly influenced by elevated cholesterol sulfate levels. 15 However, neither theory explains why the characteristic posterior corneal stromal changes do not appear in all individuals with XLI.
To the best of our knowledge, this is the first reported case of pre-Descemet corneal dystrophy associated with XLI in which the diagnosis was confirmed by the identification of a deletion of STS. Deletion of a portion of the STS coding region has been described in 2 patients with XLI, although neither of these patients demonstrated any of the ocular abnormalities associated with XLI, including pre-Descemet corneal dystrophy. 21, 22 A missense mutation in exon 8 of STS has been identified in a female carrier and affected son who both demonstrated "filiform corneal opacities." 23 To the best of our knowledge, this represents the only point mutation in STS associated with pre-Descemet corneal dystrophy and XLI. Although several other STS point mutations have been identified in individuals with XLI, these individuals either did not have ocular findings or the reports do not describe an ocular examination. 23, 24 In the case that we report, the initial diagnosis of XLI and associated pre-Descemet corneal dystrophy was confirmed using CNV analysis after a screening for point mutations in STS indicated that the gene was deleted. Thus, microarray-based comparative genomic hybridization offers ophthalmologists and other clinicians a rapid and relatively inexpensive means to confirm or refute a presumptive clinical diagnosis. Identification of the size of the deletion and the involved genes also provides insight into the basis for the variation in clinical features associated with phenotypically diverse inherited disorders, such as XLI.
